Attack aircraft model by Ilyushin; sans suffixe version of Il-2 family.
1
Results: IL2 was usually not detectable in any of the disease groups.
2
Conclusions: IL2Ra could be safely and effectively used after liver transplantation in various situations.
3
The regimen included neither lymphocyte-depleting conditioning nor administration of IL2.
4
Under these conditions, rH-IL2 alone activated macrophages to a tumoricidal state in a concentration dependent fashion.
5
Among low-risk recipients with low-risk donors there was no difference in outcomes between IL2RA and rATG.
1
In addition, EMFs increased the expression of IL-2 by the T cells.
2
Coincidentally, a deletion of this region enhanced the IL-2-induced expression of beta-casein.
3
The decreasing tolerance to IL-2 was associated primarily with elevations in creatinine.
4
Finally, despite impaired Rel-A translocation, T cells were capable of transcribing IL-2.
5
A decreased ability to secrete IL-2 suggests an element of infection-associated immunosuppression.
6
Preexisting antitumor precursors did not decrease when peptide plus IL-2 was administered.
7
Thyroid function should be measured routinely in cancer patients receiving IL-2-based treatment.
8
However, the relation between IL-2 and DC system needs to be further understood.
9
IL-2 was thought to be the causative agent in most cases of fever.
10
Low-dose IL-2 therapy has produced disappointing clinical response rates in melanoma.
11
Serum levels of sIL-2Ra and sTNF-RII were increased in volunteers who developed illness.
12
This study identified subsets of patients who tolerated less IL-2 with repeated courses.
13
Infusion of the cells was safe whether administered alone or with IL-2 subcutaneously.
14
This protection was not reversible by systemic administration of high doses of IL-2.
15
Similar inhibition of IL-2-induced proliferation was observed in the lungs, kidneys, and spleen.
16
The two IL-2 dose groups were combined for the primary analysis.